The biotech market made a comeback in 2024, recovering from a slump a year earlier. What will the IPO window look like in 2025? During this panel discussion, we will examine the performance of companies that went public in the second half of 2024 and how their success or challenges are impacting other startups’ decisions on whether to go public themselves
With advancements in platform technologies and automation, the cell and gene therapy space is poised for changes. During this panel discussion, industry leaders will explore challenges and share insights on navigating regulatory hurdles, optimizing manufacturing and leveraging emerging technologies to address broader disease states.
